Medindia

X

Reportlinker Adds Protein Kinase Therapeutics in Oncology - Where to Commercialize?

Wednesday, August 25, 2010 General News J E 4
Advertisement


NEW YORK, Aug. 25 Reportlinker.com announces that a new market research report is available in its catalogue:

Protein Kinase Therapeutics in Oncology - Where to Commercialize?

http://www.reportlinker.com/p0284973/Protein-Kinase-Therapeutics-in-Oncology---Where-to-Commercialize.html

This report comprises defined and up to date development strategies for 409 protein kinase drugs (990 projects) within the portfolio of 160 investigators, from Ceased to Marketed. The report extensively analyses 133 identified targets of protein kinase drugs, organized into 200 drug target profiles, and assesses them in 57 different cancer indications.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It serves as an external commercial advocate for pharmaceutical companies' portfolio planning and new product planning by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report will also be an important part of creating and implementing a market development plan for any protein kinase drug in oncology to ensure that the optimal market conditions exist by the time the product is commercialized.

1 Executive Summary 3

2 About Cancer Highlights 4

3 Methodologies 6

4 Table of Contents 8

4.1 List of Figures 19

4.2 List of Tables 19

5 Introduction 30

5.1 The Scope of this Report 30

5.2 Definitions 35

5.3 Abbreviations 35

6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment 36

6.1 Drug Repositioning in Oncology 36

6.2 Introduction to Protein Kinase Therapeutic Targets in Oncology 37

6.2.1 Carboxy-lyase Activity Targets 39

6.2.2 Catalytic Activity Targets 40

6.2.3 Cell Adhesion Molecule Activity Targets 43

6.2.4 Chaperone Activity Targets 45

6.2.5 Cysteine-Type Peptidase Activity Targets 47

6.2.6 DNA Topoisomerase Activity Targets 49

6.2.7 G-Protein Coupled Receptor Activity Targets 51

6.2.8 Growth Factor Activity Targets 52

6.2.9 Hydrolase Activity Targets 57

6.2.10 Kinase Activity Targets 58

6.2.11 Kinase Regulator Activity Targets 68

6.2.12 Lipid Kinase Activity Targets 72

6.2.13 Lipid Phosphatase Activity Targets 79

6.2.14 Oxidoreductase Activity Targets 80

6.2.15 Peroxidase Activity Targets 81

6.2.16 Protein Binding Targets 82

6.2.17 Protein Serine/Threonine Kinase Activity Targets 84

6.2.18 Protein Threonine/Tyrosine Kinase Activity Targets 144

6.2.19 Protein Tyrosine/Serine/Threonine Phosphatase Activity Targets 147

6.2.20 Protein-Tyrosine Kinase Activity Targets 148

6.2.21 Protein-Tyrosine Kinase Activity Targets 150

6.2.22 Receptor Activity Targets 174

6.2.23 Receptor Binding Targets 176

6.2.24 Receptor Signaling Complex Scaffold Activity Targets 177

6.2.25 Structural Constituent of Cytoskeleton Targets 178

6.2.26 Transcription Factor Activity Targets 179

6.2.27 Transcription Regulator Activity Targets 192

6.2.28 Translation Regulator Activity Targets 193

6.2.29 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 194

6.2.30 Transporter Activity Targets 254

6.3 The Cancer Genome Project and Protein Kinase Therapeutic Targets in Oncology 258

6.3.1 Protein Kinase Therapeutic Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 258

6.4 Structure-based Drug Design in Protein Kinase Therapeutics is Stimulated by Available Structure Data on Biological Targets 262

6.5 Target-Target Interactions among Identified Protein Kinase Therapeutics Targets in Oncology 265

6.6 The Drug-Target Interactome 270

6.7 Protein Expression Levels of Identified Protein Kinase Therapeutic Targets in Oncology 275

6.8 Pathway Analysis of Cancer Protein Kinase Therapeutic Targets 279

7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Cancer Protein Kinase Therapeutic Pipeline? 337

7.1 Terminated Drug Target Profiles of Cancer Protein Kinase Drugs 340

7.2 Pre-Registration to being Marketed: New and Unique Drug Target Profiles of Protein Kinase Therapeutics in Oncology 345

7.3 Phase III Clinical Development: New and Unique Drug Target Profiles of Protein Kinase Therapeutics in Oncology 347

7.4 Phase II Clinical Development: New and Unique Drug Target Profiles of Protein Kinase Therapeutics in Oncology 350

7.5 Phase I Clinical Development: New and Unique Drug Target Profiles of Protein Kinase Therapeutics in Oncology 356

7.6 Preclinical Development: New and Unique Drug Target Profiles of Protein Kinase Therapeutics in Oncology 364

7.7 Development Profiles of All Protein Kinase Drugs in Oncology 374

8 Compound Strategies at Work: Competitive Benchmarking of Protein Kinase Drugs in Oncology by Compound Type 408

8.1 Small Molecules 410

8.1.1 Background 410

8.1.2 Target Profiles of Small Molecular Drugs 411

8.2 Peptide/Protein Drugs 460

8.2.1 Background 460

8.2.2 Target Profiles of Peptide and Protein Drugs 461

8.3 Antibodies and Antibody-like Structures 465

8.3.1 Background 465

8.3.2 Target Profiles of Antibody Drugs 465

8.4 Nucleic Acid Therapies 469

8.4.1 Background 469

8.4.2 Target Profiles of Nucleic Acid Drugs 470

8.5 Cell and Gene Therapy 472

8.5.1 Background 472

8.5.2 Target Profiles of Cell- and Gene Therapy Drugs 473

8.6 The Competition Through Close Mechanistic Approximation of Cancer Protein Kinase Therapeutics 475

8.7 Compound Strategies based on Sub-Cellular Localization of Protein Kinase Drug Targets in Oncology 489

9 Selecting Cancer Indications for Protein Kinase Therapeutics 496

9.1 Acute Lymphocytic Leukemia 499

9.2 Acute Myelogenous Leukemia 501

9.3 Adrenal Cancer 505

9.4 B-cell Lymphoma 506

9.5 Basal Cell Cancer 508

9.6 Benign prostatic hyperplasia 508

9.7 Biliary Cancer 509

9.8 Bladder Cancer 510

9.9 Bone Cancer 512

9.10 Brain Cancer 513

9.11 Breast Cancer 517

9.12 Carcinoid 525

9.13 Cervical Cancer 526

9.14 Chronic Lymphocytic Leukemia 528

9.15 Chronic Myelogenous Leukemia 530

9.16 Colorectal Cancer 533

9.17 Endometrial Cancer 541

9.18 Fallopian Tube Cancer 543

9.19 Gastrointestinal Cancer (general) 545

9.20 Gastrointestinal Stomach Cancer 547

9.21 Gastrointestinal Stromal Cancer 549

9.22 Head and Neck Cancer 551

9.23 Hodgkin's Lymphoma 554

9.24 Leiomyo Sarcoma 555

9.25 Leukemia (general) 556

9.26 Lipo Sarcoma 558

9.27 Liver Cancer 559

9.28 Lung Cancer (general) 562

9.29 Lymphoma (general) 564

9.30 Mast Cell Leukemia 565

9.31 Melanoma 566

9.32 Mesothelioma 570

9.33 Myelodysplastic Syndrome 573

9.34 Myeloma 575

9.35 Nasopharyngeal Cancer 578

9.36 Neuroblastoma Cancer 579

9.37 non-Hodgkin's Lymphoma 580

9.38 Non-Small Cell Lung Cancer 582

9.39 Oesophageal Cancer 589

9.40 Oral Cancer 592

9.41 Osteo Sarcoma 592

9.42 Ovarian Cancer 593

9.43 Pancreatic Cancer 598

9.44 Peritoneal Cancer 602

9.45 Prostate Cancer 604

9.46 Renal Cancer 609

9.47 Rhabdomyo Sarcoma 615

9.48 Sarcoma (general) 616

9.49 Small Cell Lung Cancer 619

9.50 Soft Tissue Sarcoma 621

9.51 Squamous Cell Cancer 622

9.52 Synovial Sarcoma 623

9.53 T-cell Lymphoma 624

9.54 Testicular Cancer 625

9.55 Thymoma Cancer 626

9.56 Thyroid Cancer 627

9.57 Unspecified Cancer Indication 630

10 Portfolio Planning: Competitive Benchmarking of Protein Kinase Cancer Therapeutic Pipeline by Investigator 650

10.1 4SC 654

10.2 AB Science 658

10.3 Abbott 662

10.4 Abiogen 670

10.5 Abraxis BioScience 674

10.6 Advenchen 679

10.7 AEgera 682

10.8 Aeterna Zentaris 686

10.9 Aida Pharmaceuticals 693

10.10 Alethia Biotherapeutics 696

10.11 Alfacell 699

10.12 AlphaVax 702

10.13 Ambit Biosciences 706

10.14 Amgen 713

10.15 Amphora 723

10.16 Apthera 732

10.17 Ariad 736

10.18 Arno Therapeutics 744

10.19 ArQule 747

10.20 Array BioPharma 752

10.21 Astellas 757

10.22 Astex Therapeutics 760

10.23 AstraZeneca 769

10.24 Avalon 784

10.25 Bayer 787

10.26 Benitec 794

10.27 Berkeley Lab 798

10.28 BioAxone 801

10.29 Biotecnol 804

10.30 Biotica Technology 808

10.31 Boehringer Ingelheim 812

10.32 Bristol-Myers Squibb 820

10.33 BTG 837

10.34 Calistoga Pharmaceuticals 840

10.35 Callisto Pharmaceuticals 843

10.36 Cambrex 846

10.37 CanBas 849

10.38 Cancer Research Technology 852

10.39 Catalyst Biosciences 857

10.40 Celgene 861

10.41 Cell Therapeutics 864

10.42 Cephalon 867

10.43 Chroma Therapeutics 874

10.44 CompleGen 878

10.45 Compugen 883

10.46 CoNCERT Pharmaceuticals 887

10.47 Curis 891

10.48 Cyclacel 895

10.49 Cylene Pharmaceuticals 900

10.50 Cytokine PharmaSciences 903

10.51 Cytopia 907

10.52 Dainippon Sumitomo Pharma 911

10.53 Deciphera Pharmaceuticals 914

10.54 DeveloGen 923

10.55 Dyax 927

10.56 Eisai 930

10.57 Elara Pharmaceuticals 937

10.58 Eli Lilly 940

10.59 Enkam Pharmaceuticals 948

10.60 EntreMed 952

10.61 Exelixis 955

10.62 Galapagos 970

10.63 Genentech 973

10.64 Generex 977

10.65 GlaxoSmithKline 981

10.66 GlycoGenesys 991

10.67 GPC Biotech 995

10.68 Hanmi 998

10.69 Hoffmann-La Roche 1003

10.70 Hutchison China MediTech 1011

10.71 Idera Pharmaceuticals 1014

10.72 ImClone Systems 1017

10.73 ImmunoFrontier 1023

10.74 Incyte Corporation 1027

10.75 Inhibiton Therapeutics 1030

10.76 Inovio 1033

10.77 Insmed 1036

10.78 InterMune 1039

10.79 ISU ABXIS 1042

10.80 Johnson & Johnson 1046

10.81 KAI Pharmaceuticals 1051

10.82 Kalypsys 1054

10.83 Keryx Biopharmaceuticals 1057

10.84 Kiadis 1061

10.85 Kirin Pharma 1066

10.86 KuDOS 1071

10.87 Kyowa Hakko Kirin 1074

10.88 Lexicon Pharmaceuticals 1081

10.89 Locus Pharmaceuticals 1084

10.90 Lorus Therapeutics 1087

10.91 MaxoCore Pharmaceuticals 1090

10.92 Medisyn Technologies 1093

10.93 Merck & Co 1096

10.94 MethylGene 1101

10.95 Mitsubishi Tanabe Pharma 1104

10.96 Molecular LogiX 1108

10.97 NeoPharm 1112

10.98 Nerviano Medical Sciences 1116

10.99 NicOx 1120

10.100 Nidus Laboratories 1123

10.101 NIH - The US National Institute of Health 1127

10.102 Nippon Shinyaku 1130

10.103 Non-industrial Source 1134

10.104 Novartis 1137

10.105 Novogen 1154

10.106 Oncalis 1158

10.107 Onconova 1162

10.108 OncoTherapy Science 1170

10.109 Oncothyreon 1174

10.110 OSI Pharmaceuticals 1180

10.111 Pathway Therapeutics 1192

10.112 Peregrine Pharmaceuticals 1195

10.113 Pfizer 1199

10.114 Pharmacyclics 1218

10.115 PharmaGap 1222

10.116 PharmaMar 1226

10.117 Pharmexa 1231

10.118 Phytomedics 1237

10.119 Piramal 1240

10.120 PIramed 1243

10.121 Plexxikon 1247

10.122 Provid 1250

10.123 QLT 1253

10.124 Quantum Pharmaceuticals 1257

10.125 Ras Therapeutics 1261

10.126 Reata Pharmaceuticals 1264

10.127 Receptor BioLogix 1268

10.128 Rexahn 1271

10.129 Rigel 1276

10.130 Sanofi-Aventis 1281

10.131 Sareum 1285

10.132 SBIO 1291

10.133 Scancell 1298

10.134 Schering-Plough 1301

10.135 Semafore Pharmaceuticals 1306

10.136 Sentinel Oncology 1313

10.137 SGX Pharmaceuticals 1316

10.138 Silence Therapeutics 1321

10.139 Sirna Therapeutics 1325

10.140 Sunesis 1328

10.141 SuperGen 1332

10.142 Supratek Pharma 1339

10.143 Switch Pharma 1342

10.144 Takeda 1346

10.145 Targa Therapeutics 1350

10.146 TargeGen 1355

10.147 Tekmira Pharmaceuticals 1358

10.148 Telik 1361

10.149 Thallion Pharmaceuticals 1366

10.150 Theryte 1369

10.151 ToolGen 1372

10.152 TopoTarget 1375

10.153 UCB 1380

10.154 VasGene Therapeutics 1384

10.155 Velacor Therapeutics 1387

10.156 Vertex Pharmaceuticals 1390

10.157 ViroMed 1394

10.158 Wyeth 1398

10.159 Xcovery 1410

10.160 Xencor 1414

11 Disclaimer 1418

12 Drug Index 1419

13 Company Index 1433

4.1 List of Figures

Figure 1: Visualization of Target-Target Interactions among Protein Kinase Drug Targets in Oncology 269

Figure 2: The Drug-Protein Interactome of Protein Kinase Drugs -Clusters I 272

Figure 3: The Drug-Protein Interactome of Protein Kinase Drugs - Clusters II 273

Figure 4: Head-to-Head Targeting Interactome of Protein Kinase Drugs 274

Figure 5: Distribution of Compound Types among Protein Kinase Drugs in Oncology 489

Figure 6: Primary Sub-cellular Localization of Drug Targets 490

4.2 List of Tables

Table 1: Competitive Pressure Force among Protein Kinase Drugs in Oncology 29

Table 2: Overall Breakdown of the Included Protein Kinase Pipeline by Cancer Indication and Stage of Development 29

Table 3: Overview of Drug Target Profile Themes 36

Table 4: Terminally Ceased Therapeutic Protein Kinase Targets in Oncology 37

Table 5: Drug Targets of Protein Kinase Drugs in Oncology Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census 258

Table 6: Identity of Protein Kinase Drug Targets with Available Biological Structures 261

Table 7: Number of Target-Target Interactions among Protein Kinase Drug Targets in Oncology 264

Table 8: Drug-Protein Interactome Clusters 269

Table 9: Protein Kinase Drug Targets with Available Protein Expression Profiles 274

Table 10: Pathway Summary 278

Table 11: Drug Targets without any Identified Assigned Pathways 278

Table 12: Pathway Profiles According to BioCarta of Protein Kinase Drug Targets in Oncology 279

Table 13: Pathway Profiles According to KEGG of Protein Kinase Drug Targets in Oncology 299

Table 14: Pathway Profiles According to NetPath of Protein Kinase Drug Targets in Oncology 331

Table 15: Number of Drug Target Profiles by their Highest Developmental Stage and Uniqueness 336

Table 16: Top Competitive Protein Kinase Target Profiles in Oncology 337

Table 17: Terminated Drug Target Strategies of Protein Kinase Drugs in Oncology 339

Table 18 New and Unique Protein Kinase Target Strategies in Cancer Currently in Pre-Registration to Marketed 344

Table 19: The Competition Through Close Mechanistic Approximation Between Marketed Protein Kinase Drugs in Oncology 345

Table 20: New and Unique Protein Kinase Target Strategies in Cancer Currently in Phase III Clinical Development 346

Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Protein Kinase Drugs in Oncology 347

Table 22: New and Unique Protein Kinase Target Strategies in Cancer Currently in Phase II Clinical Development 349

Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Protein Kinase Drugs in Oncology 352

Table 24 New and Unique Protein Kinase Target Strategies in Cancer Currently in Phase I Clinical Development 355

Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Protein Kinase Drugs in Oncology 360

Table 26: New and Unique Protein Kinase Target Strategies in Oncology Currently in Preclinical Development 363

Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Protein Kinase Drugs in Oncology 368

Table 28: The Progression, Maturity and Competitive Comparison of Protein Kinase Drug Target Profiles in Cancer Drug Development 373

Table 29: Overview of Compound Strategy Competition Among Protein Kinase Drugs in Oncology 408

Table 30: Overview of the Competitive Landscape of Small Molecular Protein Kinase Drugs in Oncology 410

Table 31: Head-to-Head Target Competition Between Small Molecule Protein Kinase Drugs for the Treatment of Cancer 411

Table 32: The Competition Through Close Mechanistic Approximation Between Small Molecule Drugs of Protein Kinase Therapeutics in Oncology 416

Table 33: The Progression, Maturity and Competitive Comparison of Target Profiles of Small Molecule Protein Kinase Drugs in Development 429

Table 34: Overview of the Competitive Landscape of Peptide Based Protein Kinase Drugs in Oncology 460

Table 35: The Progression, Maturity and Competitive Comparison of Target Profiles of Peptide Based Protein Kinase Drugs in Development 460

Table 36: Overview of the Competitive Landscape of Protein Based Protein Kinase Drugs in Oncology 462

Table 37: The Competition Through Close Mechanistic Approximation Between Protein Based Protein Kinase Drugs in Oncology 462

Table 38: The Progression, Maturity and Competitive Comparison of Protein Based Protein Kinase Drugs in Development 463

Table 39: Overview of the Competitive Landscape of Antibody Protein Kinase Drugs in Oncology 464

Table 40: The Competition Through Close Mechanistic Approximation Between Antibody Protein Kinase Drugs in Oncology 465

Table 41: The Progression, Maturity and Competitive Comparison of Target Profiles of Antibody Protein Kinase Drugs in Development 466

Table 42: Overview of the Competitive Landscape of Nucleic Acid Therapy Protein Kinase Drugs in Oncology 469

Table 43: The Competition Through Close Mechanistic Approximation Between Nucleic Acid Therapy Protein Kinase Drugs in Oncology 469

Table 44: The Progression, Maturity and Competitive Comparison of Target Profiles of Nucleic Acid Protein Kinase Drugs in Development 470

Table 45: Potential Forms of Cell Therapy 471

Table 46: Vectors in Gene Therapy 472

Table 47: The Progression, Maturity and Competitive Comparison of Target Profiles of Cell Therapy Based Protein Kinase Drugs in Development 472

Table 48: Overview of the Competitive Landscape of Gene Therapy Protein Kinase Drugs in Oncology 472

Table 49: The Progression, Maturity and Competitive Comparison of Target Profiles of Gene Therapy Based Protein Kinase Drugs in Development 473

Table 50: The Competition Through Close Mechanistic Approximation Among All Protein Kinase Drugs in Oncology 474

Table 51: Compound Strategies based on Sub-Cellular Localization of Protein Kinase Drug Targets in Oncology 489

Table 52: Competitive Summary of Protein Kinase Drugs by Cancer Indication 495

Table 53: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Acute Lymphocytic Leukemia 498

Table 54: The Competition through Close Mechanistic Approximation between Acute Lymphocytic Leukemia Drugs 499

Table 55: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Acute Myelogenous Leukemia 500

Table 56: The Competition through Close Mechanistic Approximation between Acute Myelogenous Drugs 502

Table 57: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Adrenal Cancer 504

Table 58: Drug Target Profiles of Protein Kinase Drugs for the Treatment of B-cell Lymphoma 505

Table 59: The Competition through Close Mechanistic Approximation between B-cell Lymphoma Drugs 506

Table 60: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Basal Cell Cancer 507

Table 61: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Benign Prostatic Hyperplasia 507

Table 62: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Biliary Cancer 508

Table 63: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Bladder Cancer 509

Table 64: The Competition through Close Mechanistic Approximation between Bladder Cancer Drugs 510

Table 65: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Bone Cancer 511

Table 66: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Brain Cancer 512

Table 67: The Competition through Close Mechanistic Approximation between Brain Cancer Drugs 514

Table 68: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Breast Cancer 516

Table 69: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs 521

Table 70: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Carcinoid 524

Table 71: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Cervical Cancer 525

Table 72: The Competition through Close Mechanistic Approximation between Cervical Cancer Drugs 526

Table 73: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Chronic Lymphocytic Leukemia 527

Table 74: The Competition through Close Mechanistic Approximation between Chronic Lymphocytic Leukemia Drugs 528

Table 75: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Chronic Myelogenous Leukemia 529

Table 76: The Competition through Close Mechanistic Approximation between Chronic Myelogenous Leukemia Drugs 531

Table 77: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Colorectal Cancer 532

Table 78: The Competition through Close Mechanistic Approximation between Colorectal Cancer Drugs 538

Table 79: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Endometrial Cancer 540

Table 80: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Fallopian Tube Cancer 542

Table 81: The Competition through Close Mechanistic Approximation between Fallopian Tube Cancer Drugs 543

Table 82: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Gastrointestinal Cancer (general) 544

Table 83: The Competition through Close Mechanistic Approximation between Gastrointestinal Cancer (general) Drugs 545

Table 84: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Gastrointestinal Stomach Cancer 546

Table 85: The Competition through Close Mechanistic Approximation between Gastrointestinal Stomach Cancer Drugs 547

Table 86: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Gastrointestinal Stromal Cancer 548

Table 87: The Competition through Close Mechanistic Approximation between Gastrointestinal Stromal Cancer Drugs 549

Table 88: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Head and Neck Cancer 550

Table 89: The Competition through Close Mechanistic Approximation between Head and Neck and Cancer Drugs 552

Table 90: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Hodgkin's Lymphoma 553

Table 91: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Leiomyo Sarcoma 554

Table 92: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Leukemia (general) 555

Table 93: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Lipo Sarcoma 557

Table 94: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Liver Cancer 558

Table 95: The Competition through Close Mechanistic Approximation between Liver Cancer Drugs 560

Table 96: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Lung Cancer (general) 561

Table 97: The Competition through Close Mechanistic Approximation between Lung Cancer (general) Drugs 562

Table 98: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Lymphoma (general) 563

Table 99: The Competition through Close Mechanistic Approximation between Lymphoma (general) Drugs 564

Table 100: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Mast Cell Leukemia 564

Table 101: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Melanoma 565

Table 102: The Competition through Close Mechanistic Approximation between Melanoma Cancer Drugs 567

Table 103: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Mesothelioma 569

Table 104: The Competition through Close Mechanistic Approximation between Mesothelioma Drugs 571

Table 105: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Myelodysplastic Syndrome 572

Table 106: The Competition through Close Mechanistic Approximation between Myelodysplastic Syndrome Drugs 573

Table 107: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Myeloma 574

Table 108: The Competition through Close Mechanistic Approximation between Myeloma Drugs 576

Table 109: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Nasopharyngeal Cancer 577

Table 110: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Neuroblastoma Cancer 578

Table 111: Drug Target Profiles of Protein Kinase Drugs for the Treatment of non-Hodgkin's Lymphoma 579

Table 112: The Competition through Close Mechanistic Approximation between non-Hodgkin's Lymphoma Drugs 580

Table 113: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Non-Small Cell Lung Cancer 581

Table 114: The Competition through Close Mechanistic Approximation between Non-Small Cell Lung Cancer Drug 585

Table 115: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Oesophageal Cancer 588

Table 116: The Competition through Close Mechanistic Approximation between Oesophageal Cancer Drugs 590

Table 117: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Oral Cancer 591

Table 118: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Osteo Sarcoma 591

Table 119: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Ovarian Cancer 592

Table 120: The Competition through Close Mechanistic Approximation between Ovarian Cancer Drugs 595

Table 121: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Pancreatic Cancer 597

Table 122: The Competition through Close Mechanistic Approximation between Pancreatic Cancer Drugs 600

Table 123: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Peritoneal Cancer 601

Table 124: The Competition through Close Mechanistic Approximation between Peritoneal Cancer Drugs 602

Table 125: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Prostate Cancer 603

Table 126: The Competition through Close Mechanistic Approximation between Prostate Cancer Drugs 606

Table 127: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Renal Cancer 608

Table 128: The Competition through Close Mechanistic Approximation between Renal Cancer Drugs 611

Table 129: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Rhabdomyo Sarcoma 614

Table 130: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Sarcoma (general) 615

Table 131: The Competition through Close Mechanistic Approximation between Sarcoma (general) Drugs 617

Table 132: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Small Cell Lung Cancer 618

Table 133: The Competition through Close Mechanistic Approximation between Small Cell Lung Cancer Drugs 619

Table 134: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Soft Tissue Sarcoma 620

Table 135: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Squamous Cell Cancer 621

Table 136: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Synovial Sarcoma 622

Table 137: Drug Target Profiles of Protein Kinase Drugs for the Treatment of T-cell Lymphoma 623

Table 138: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Testicular Cancer 624

Table 139: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Thymoma Cancer 625

Table 140: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Thyroid Cancer 626

Table 141: The Competition through Close Mechanistic Approximation between Thyroid Cancer Drugs 628

Table 142: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Unspecified Cancer Indication 629

Table 143: The Competition through Close Mechanistic Approximation between Unspecified Cancer Indication Drugs 640

Table 144: 4SC's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 653

Table 145: AB Science's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 657

Table 146: Abbott's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 661

Table 147: Abiogen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 669

Table 148: Abraxis BioScience's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 673

Table 149: Advenchen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 678

Table 150: AEgera's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 681

Table 151: Aeterna Zentaris' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 685

Table 152: Aida Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 692

Table 153: Alethia Biotherapeutics' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 695

Table 154: Alfacell's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 698

Table 155: AlphaVax's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 701

Table 156: Ambit Biosciences' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 705

Table 157: Amgen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 712

Table 158: Amphora's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 722

Table 159: Apthera's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 731

Table 160: Ariad's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 735

Table 161: Arno Therapeutics' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 743

Table 162: ArQule's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 746

Table 163: Array BioPharma's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 751

Table 164: Astellas' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 756

Table 165: Astex Therapeutics' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 759

Table 166: AstraZeneca's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 768

Table 167: Avalon's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 783

Table 168: Bayer's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 786

Table 169: Benitec's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 793

Table 170: Berkeley Lab's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 797

Table 171: BioAxone's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 800

Table 172: Biotecnol's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 803

Table 173: Biotica Technology's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 807

Table 174: Boehringer Ingelheim's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 811

Table 175: Bristol-Myers Squibb's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 819

Table 176: BTG's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 836

Table 177: Calistoga Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 839

Table 178: Callisto Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 842

Table 179: Cambrex's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 845

Table 180: CanBas' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 848

Table 181: Cancer Research Technology's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 851

Table 182: Catalyst Biosciences' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 856

Table 183: Celgene's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 860

Table 184: Cell Therapeutics' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 863

Table 185: Cephalon's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 866

Table 186: Chroma Therapeutics' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 873

Table 187: CompleGen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 877

Table 188: Compugen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 882

Table 189: CoNCERT Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 886

Table 190: Curis' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 890

Table 191: Cyclacel's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 894

Table 192: Cylene Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 899

Table 193: Cytokine PharmaSciences' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 902

Table 194: Cytopia's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 906

Table 195: Dainippon Sumitomo Pharma's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 910

Table 196: Deciphera Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 913

Table 197: DeveloGen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 922

Table 198: Dyax's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 926

Table 199: Eisai's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 929

Table 200: Elara Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 936

Table 201: Eli Lilly's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 939

Table 202: Enkam Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 947

Table 203: EntreMed's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 951

Table 204: Exelixis' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 954

Table 205: Galapagos' Included Protein Kinase Drugs in Oncology and Comp

To order this report:

Biotechnology Industry: Protein Kinase Therapeutics in Oncology - Where to Commercialize?

Biotechnology Business News

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Grants Office Launches Suite of Free Funding Infor...
S
Pharmacovigilance Breakthrough: Henry Ford Health ...